research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Many components of the insulin signaling pathway, including β-catenin, IR-β, IRS1, Akt, PDK1, and the p110α subunit of PI3K were found to be directly modified by O-GlcNAc. Insulin signaling has also been reported to lead to OGT tyrosine phosphorylation and OGT activation, resulting in increased O-GlcNAc levels. As PUGNAc also inhibits lysosomal β-hexosaminidases, the OGA-selective inhibitor NButGT was developed to further probe the relationship between O-GlcNAc and insulin signaling in 3T3-L1 adipocytes. This study also found that PUGNAc resulted in impaired insulin signaling, but NButGT did not, as measured by changes in phosphorylation of Akt T308, suggesting that the effects observed with PUGNAc may be due to off-target effects besides OGA inhibition.
In intelligent mammals, such as primates, the cerebrum is larger relative to the rest of the brain. Intelligence itself is not easy to define, but indications of intelligence include the ability to learn, matched with behavioral flexibility. Rats, for example, are considered to be highly intelligent, as they can learn and perform new tasks, an ability that may be important when they first colonize a fresh habitat. In some mammals, food gathering appears to be related to intelligence: a deer feeding on plants has a brain smaller than a cat, which must think to outwit its prey.
=== Drowsiness === Clonazepam, like other benzodiazepines, may impair a person's ability to drive or operate machinery. The central nervous system depressing effects of the drug can be intensified by alcohol consumption, so alcohol should be avoided while taking this medication. Benzodiazepines have been shown to cause dependence. Patients dependent on clonazepam should be slowly titrated off under the supervision of a qualified healthcare professional to reduce the intensity of withdrawal or rebound symptoms.
Sources: en.wikipedia.org
Since its founding in 1517 on the orders of François I, Le Havre has continued to grow: today it measures 27 km (17 mi) from east to west, about 5 km (3 mi) from north to south with an area of 10,000 hectares (24,711 acres). The last big project called Port 2000 increased the handling capacity for containers. The port provides 16,000 direct jobs to the Le Havre region, to which must be added indirect jobs in industry and transport. With approximately 3,000 employees in 2006, the activities of distribution and warehousing provide more jobs, followed by road transport (2,420 jobs) and handling (2,319 jobs). In 2011, 715,279 passengers passed through the port of Le Havre and there were 95 visits by cruise ships carrying 185,000 passengers. The port expects 110 cruise ship calls in 2012. Created in 1934, the leisure boat harbour of Le Havre is located to the west and is the largest French boat harbour in the Channel with a capacity of 1,160 moorings. Finally, there is a small fishing port in the Saint-François district and a Hawker centre.
Little gastrin I also known as '''gastrin-17''' or ''G-17''', is a 17-amino acid Peptide hormone and the most abundant form of gastrin found in healthy individuals.It is produced primarily by G-cells in the Gastric antrum and plays a key role in regulating gastric acid secretion and digestion. The existence of gastrin was first proposed by British physiologist John Sydney Edkins in 1905, though its structure was not fully worked out until the 1960s. Little gastrin I is synthesized from a larger precursor protein called preprogastrin, which undergoes several processing steps before producing the mature hormone. It stimulates parietal cells in the stomach to secrete hydrochloric acid and is involved in gastric motility and the release of pepsin and intrinsic factor. Its release is triggered by food intake and inhibited by low stomach pH, forming a negative feedback loop. Abnormally high levels of gastrin, known as hypergastrinemia, are associated with conditions such as atrophic gastritis, pernicious anemia, and gastric cancer.
=== Significance in biofilms === Afterwards, as biofilm becomes established, EPS provides physical stability and resistance to mechanical removal, antimicrobials, and host immunity. Exopolysaccharides and environmental DNA (eDNA) contribute to viscoelasticity of mature biofilms so that detachment of biofilm from the substratum will be challenging even under sustained fluid shear stress or high mechanical pressure. In addition to mechanical resistance, EPS also promotes protection against antimicrobials and enhanced drug tolerance. Antimicrobials cannot diffuse through the EPS barrier, resulting in limited drug access into the deeper layers of the biofilm. Moreover, positively charged agents will bind to negatively charged EPS contributing to the antimicrobial tolerance of biofilms, and enabling inactivation or degradation of antimicrobials by enzymes present in biofilm matrix. EPS also functions as local nutrient reservoir of various biomolecules, such as fermentable polysaccharides. A study on V. cholerae in 2017 suggested that due to osmotic pressure differences in V. cholerae biofilms, the microbial colonies physically swell, therefore maximizing their contact with nutritious surfaces and thus, nutrient uptake.
The game remained in PC Data's weekly top 10 until the week of March 21 and dropped to position 11 for March as a whole. In the United Kingdom, it placed second in February—behind the debut of Baldur's Gate—and fifth in March. In April, it claimed #3 on Chart-Track's rankings and dropped to #16 on those of PC Data. On April 23, Sierra announced that global sales of Half-Life had reached almost 1 million copies. After maintaining the 16th place for May in the U.S., Half-Life exited PC Data's monthly top 20 in June. Half-Life became the fifth-best-selling PC game of the first half of 1999 in the U.S. Its domestic sales during 1999 reached 290,000 copies by the end of September. During 1999, it was the fifth-best-selling PC game in the U.S., with sales of 445,123 copies. These sales brought in revenues of $16.6 million, the sixth-highest gross that year for a PC game in the U.S. The following year, it was the 16th-best-selling PC game in the U.S., selling another 286,593 copies and earning $8.98 million. Half-Life dominated FPS sales of the period. Robert M. Atkins, the design lead of the FPS Sin, released shortly before Half-Life, said: "Half-Life just crushed the market. It completely changed the first-person shooter narratives." The PlayStation 2 version received a "Silver" sales award from the Entertainment and Leisure Software Publishers Association (ELSPA), indicating sales of 100,000 copies in the UK Half-Life's global sales reached 2.5 million copies by July 2001.
Sources: en.wikipedia.org
Eosinophilia (6%) Thrombocytosis (5.1%) Elevations in liver enzymes (3.1–3.3%) Diarrhea (2.7%) Leukopenia (2.1%) Elevation in BUN (1.2%) Local reactions: pain, tenderness, irritation (1%) Rash (1.7%) Some less frequently reported adverse events (incidence < 1%) include phlebitis, itchiness, fever, chills, nausea, vomiting, elevations of bilirubin, elevations in creatinine, headache and dizziness. Ceftriaxone may precipitate in bile, causing biliary sludge, biliary pseudolithiasis, and gallstones, especially in children. Hypoprothrombinaemia and bleeding are specific side effects. Haemolysis is reported. It has also been reported to cause post kidney failure in children. Like other antibiotics, ceftriaxone use can result in Clostridioides difficile-associated diarrhea ranging from mild diarrhea to fatal colitis. In this regard it has been reported that shifting from ceftriaxone to cefotaxime would have a lower impact on C. difficile infection rates, since cefotaxime is almost entirely excreted by the kidneys while ceftriaxone has a 45% biliary excretion
== National laws, regulations, and management == Laws governing aquaculture practices vary greatly by country and are often not closely regulated or easily traceable. In the United States, land-based and nearshore aquaculture is regulated at the federal and state levels; no national laws govern offshore aquaculture in U.S. exclusive economic zone waters. In June 2011, the Department of Commerce and National Oceanic and Atmospheric Administration released national aquaculture policies to address this issue and "to meet the growing demand for healthy seafood, to create jobs in coastal communities, and restore vital ecosystems." Large aquaculture facilities (i.e. those producing 20,000 pounds (9,100 kg) per year) which discharge wastewater are required to obtain permits pursuant to the Clean Water Act. Facilities that produce at least 100,000 pounds (45,000 kg) of fish, molluscs or crustaceans a year are subject to specific national discharge standards. Other permitted facilities are subject to effluent limitations that are developed on a case-by-case basis.
The Lord Ramage series by Dudley Pope takes place during the Napoleonic Wars. Jeanette Winterson's 1987 novel The Passion. Georgette Heyer's 1937 novel An Infamous Army recounts the fortunes of a family in the run-up to and during the course of, the Battle of Waterloo. Heyer's novel is noted for its meticulous research on the progress of the battle, combining her noted period romance writing with her detailed research into regency history. The Battle (French: La Bataille) is a historical novel by the French author Patrick Rambaud that was first published in 1997 and again in English in 2000. The book describes the 1809 Battle of Aspern-Essling between the French Empire under Napoleon and the Austrian Empire. The novel was awarded the Prix Goncourt and the Grand Prix du roman de l'Académie française for 1997. In Jasper Kent's novel Twelve, 1812 Russian Invasion serves as a base story for the book. In later books from The Danilov Quintet, this war is constantly mentioned. The Fighting Sail series by Alaric Bond portrays life and action aboard Royal Naval vessels during the Revolutionary and Napoleonic Wars. From the lower decks to the quarterdeck Bond's detailed settings are realistic. Narratives are told not just from a commissioned officer's point of view but include varied perspectives, including warranted officers, ordinary and able seamen, marines, supernumeraries, and women aboard presenting a broader, more complete picture of the Georgian Navy.
=== Implications in cancer development === There is a growing body of evidence supporting the role of GST, particularly GSTP, in cancer development and chemotherapeutic resistance. The link between GSTP and cancer is most obvious in the overexpression of GSTP in many cancers, but it is also supported by the fact that the transformed phenotype of tumor cells is associated with aberrantly regulated kinase signaling pathways and cellular addiction to overexpressed proteins. That most anti-cancer drugs are poor substrates for GSTP indicates that the role of elevated GSTP in many tumor cell lines is not to detoxify the compounds, but must have another purpose; this hypothesis is also given credence by the common finding of GSTP overexpression in tumor cell lines that are not drug resistant.
Abrocitinib, sold under the brand name Cibinqo, is a medication used for the treatment of atopic dermatitis (eczema). It is a Janus kinase inhibitor and it was developed by Pfizer. It is taken by mouth. The most common side effects include nausea (feeling sick), headache, acne, herpes simplex (viral infection of the mouth or the genitals), increased levels of creatine phosphokinase in the blood (an enzyme released into the blood when muscle is damaged), vomiting, dizziness and pain in the upper belly. Abrocitinib was approved for medical use in the European Union in December 2021, and in the United States in January 2022.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.